Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
ACTIVE_NOT_RECRUITING
Status
Conditions
- Acute Myeloid Leukemia
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Chronic Eosinophilic Leukemia, Not Otherwise Specified
- Chronic Myelomonocytic Leukemia
- Chronic Neutrophilic Leukemia
- Essential Thrombocythemia
- Myelodysplastic Syndrome
- Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Myeloid Neoplasm
- Myeloproliferative Neoplasm
- Myeloproliferative Neoplasm, Unclassifiable
- Overt Primary Myelofibrosis
- Polycythemia Vera
- Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase
- Prefibrotic/Early Primary Myelofibrosis
Interventions
- DRUG: Azacitidine
- DRUG: Pevonedistat
- DRUG: Venetoclax
Sponsor
M.D. Anderson Cancer Center
Collaborators